New Parkinson's Drug Approved
— Treatment improves "off" time when used as add-on
SILVER SPRING, Md. – The FDA approved istradefylline (Nourianz) as an add-on treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing "off" episodes, the agency announced late Tuesday.
Istradefylline is an orally administered, selective adenosine A2Areceptor antagonist and has been marketed in Japan since 2013 as adjunctive treatment to levodopa-containing products for Parkinson's patients.
No comments:
Post a Comment